


Mamounas, et al: Breast Cancer Index and Prediction of Benefit from Extended Aromatase Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer: NRG Oncology/NSABP B-42

Supplementary Fig. S2



Supplementary Fig. S2. Exploratory Kaplan-Meier analysis based on **A**, any new primary cancer and **B**, new breast primary cancer comparing extended letrozole vs placebo in the overall Breast Cancer Index (BCI) NSABP B-42 translational cohort.